Evidence map›Paper›PMID 26309599›Full record

ArticleInternational journal of clinical and experimental medicine2015

Clinical analysis and prognostic significance of L-asparaginase containing multidrug chemotherapy regimen in incipient peripheral T-cell lymphoma.

Guoli Yao, De Zhou, Meng Zhou, Changqian Bao, Donghua He, Li Li, Jingjing Zhu, Jinsong He, Jimin Shi, Weiyan Zheng and 4 more

Abstract read
PubMed Full text at PMC
In one paragraph

Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Therapeutic options in peripheral T cell lymphoma.Journal of hematology & oncology · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Guoli YaoDepartment of Hematology, The First Affiliated Hospital of Medical School of Zhejiang University No.79 Qingchun Road, Hangzhou 310003, Zhejiang, China ; Department of Hematology, The First People's Hospital of Yuhang District Hangzhou 311100, Zhejiang, China.
De ZhouDepartment of Hematology, The First Affiliated Hospital of Medical School of Zhejiang University No.79 Qingchun Road, Hangzhou 310003, Zhejiang, China.
Meng ZhouDepartment of Hematology, The First Affiliated Hospital of Medical School of Zhejiang University No.79 Qingchun Road, Hangzhou 310003, Zhejiang, China.
Changqian BaoDepartment of Hematology, The First Affiliated Hospital of Medical School of Zhejiang University No.79 Qingchun Road, Hangzhou 310003, Zhejiang, China.
Donghua HeDepartment of Hematology, The First Affiliated Hospital of Medical School of Zhejiang University No.79 Qingchun Road, Hangzhou 310003, Zhejiang, China.
Li LiDepartment of Hematology, The First Affiliated Hospital of Medical School of Zhejiang University No.79 Qingchun Road, Hangzhou 310003, Zhejiang, China.
Jingjing ZhuDepartment of Hematology, The First Affiliated Hospital of Medical School of Zhejiang University No.79 Qingchun Road, Hangzhou 310003, Zhejiang, China.
Jinsong HeDepartment of Hematology, The First Affiliated Hospital of Medical School of Zhejiang University No.79 Qingchun Road, Hangzhou 310003, Zhejiang, China.
Jimin ShiDepartment of Hematology, The First Affiliated Hospital of Medical School of Zhejiang University No.79 Qingchun Road, Hangzhou 310003, Zhejiang, China.
Weiyan ZhengDepartment of Hematology, The First Affiliated Hospital of Medical School of Zhejiang University No.79 Qingchun Road, Hangzhou 310003, Zhejiang, China.
Zhen CaiDepartment of Hematology, The First Affiliated Hospital of Medical School of Zhejiang University No.79 Qingchun Road, Hangzhou 310003, Zhejiang, China.
He HuangDepartment of Hematology, The First Affiliated Hospital of Medical School of Zhejiang University No.79 Qingchun Road, Hangzhou 310003, Zhejiang, China.
Xiujin YeDepartment of Hematology, The First Affiliated Hospital of Medical School of Zhejiang University No.79 Qingchun Road, Hangzhou 310003, Zhejiang, China.
Wanzhuo XieDepartment of Hematology, The First Affiliated Hospital of Medical School of Zhejiang University No.79 Qingchun Road, Hangzhou 310003, Zhejiang, China.
Zhejiang Chinese Medical University · CNFirst People's Hospital of Yuhang District · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo observe the clinical effects and adverse reactions, and analyze the clinical significance of L-asparaginase (L-ASP) containing multidrug chemotherapy regimen in incipient peripheral T-cell lymphoma (PTCL).

methodsA retrospective analysis was conducted of 102 patients with incipient PTCL who received L-ASP containing multidrug chemotherapy regimens or not in our hospital from January 2010 to December 2013. Complete remission (CR) rate, partial remission (PR) rate, overall remission (OR) rate, progression free survival (PFS), overall survival (OS) and adverse reactions were compared.

resultsPatients who received L-ASP containing multidrug chemotherapy (L-ASP group) had higher OR rate than those who received L-ASP-free ones (non L-ASP group) (83.3% vs 61.7%, P=0.016), particularly those at phase III/IV (82.4% vs 54.0%, P=0.007) and with an international prognostic index (IPI) score of ≥2 (82.1% vs 50.0%, P=0.006). The median survival time (OS) was 10.5 months (range, 1-47months) in L-ASP group, while 13 months (range, 0.3-68 months) in non L-ASP group, and they had no statistically significance (P=0.754). Similarly, the progression free survival time(PFS)was 10 months (range, 1-47 months) in L-ASP group,while 11 months (range, 0.3-68 months) in non L-ASP group, also had no statistically significance (P=0.414). The 3-year OS rate of L-ASP group and non L-ASP group were 48.9% and 65.0% , respectively (P=0.974) and the 3-year PFS rate of L-ASP group and non L-ASP group were 40.8% and 61.0%, respectively (P=0.479). They all had no statistically significance. The L-ASP group had more adverse reactions than the non L-ASP group, though most of them were mild and could be improved by symptomatic and supportive care.

conclusionL-ASP containing multidrug chemotherapy regimen in incipient PTCL showed a better short-term effect and controllable adverse reactions. A large prospective clinical trial of use L-ASP in first-line treatment of PTCL is worthy of further research and investigation.

Indexed as

adverse reactioneffectl-asparaginaseLymphomaperipheral t-cellsafety

Identifiers

PMID26309599
PMCPMC4537992
OpenAlexW1551016957

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.